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Abstract
Background: High quality program data is critical for managing, monitoring, and evaluating national HIV treatment
programs. By 2009, the Malawi Ministry of Health had initiated more than 270,000 patients on HIV treatment at 377
sites. Quarterly supervision of these antiretroviral therapy (ART) sites ensures high quality care, but the time
currently dedicated to exhaustive record review and data cleaning detracts from other critical components. The
exhaustive record review is unlikely to be sustainable long term because of the resources required and increasing
number of patients on ART. This study quantifies the current levels of data quality and evaluates Lot Quality
Assurance Sampling (LQAS) as a tool to prioritize sites with low data quality, thus lowering costs while maintaining
sufficient quality for program monitoring and patient care.
Methods: In January 2010, a study team joined supervision teams at 19 sites purposely selected to reflect the
variety of ART sites. During the exhaustive data review, the time allocated to data cleaning and data discrepancies
were documented. The team then randomly sampled 76 records from each site, recording secondary outcomes
and the time required for sampling.
Results: At the 19 sites, only 1.2% of records had discrepancies in patient outcomes and 0.4% in treatment
regimen. However, data cleaning took 28.5 hours in total, suggesting that data cleaning for all 377 ART sites would
require over 350 supervision-hours quarterly. The LQAS tool accurately identified the sites with the low data quality,
reduced the time for data cleaning by 70%, and allowed for reporting on secondary outcomes.
Conclusions: Most sites maintained high quality records. In spite of this, data cleaning required significant amounts
of time with little effect on program estimates of patient outcomes. LQAS conserves resources while maintaining
sufficient data quality for program assessment and management to allow for quality patient care.
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Background
In 2004, the Malawi Ministry of Health (MoH) began
the rapid expansion of the national HIV treatment pro-
gram, initiating 271,105 and retaining 198,846 patients
on antiretroviral therapy (ART) at 377 sites (279 static
and 98 mobile/outreach) by October 2009 [1]. The suc-
cessful scale-up of the Malawi ART program was made
possible through a public health approach [2]. ART eligi-
bility is determined by WHO clinical staging or a low
CD4 count. In 2009, these criteria were Stage III or IV
disease or CD4<250 cells/mm
3 (CD4<350 cells/mm
3
for pregnant women). One standard, fixed-dose first-line
regimen (stavudine, lamivudine, nevirapine in 2009) is
used for >90% of patients and standard alternative regi-
mens are used for patients who develop side effects to
the first-line regimen [3]. Experienced sites (generally
district hospitals that have been offering ART for at least
three years) also provide standard second-line regimens
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until stable on therapy (usually after six to ten months).
Two- or three-monthly appointments are scheduled
thereafter.
Two critical components of the national ART program
are 1) a standardized system for registering and monitor-
ing patients, including individual patient treatment cards
with registration and follow-up data and a clinic register
summarizing critical data for each patient [3] and 2)
quarterly supervision at all ART sites in Malawi [4].
Every quarter, ART clinic personnel perform a standar-
dized patient cohort analysis that includes aggregation of
case-finding details of patients registered during the pre-
vious quarter and since ART was first begun, as well as
treatment outcomes for the cumulative cohort. The lat-
ter analysis requires a review of all treatment cards in
order to update the clinic register and then a tally-score
on current patient outcomes. The primary outcome is
patient status, namely, alive on ART, died, stopped ART
(with clinician’s knowledge), transferred to another ART
clinic, or lost to follow-up. Secondary outcomes for
patients alive on ART include 1) ART regimen, 2) drug
adherence, 3) ART side effects, and 4) current tubercu-
losis status. A rolling cohort survival analysis is also per-
formed by counting primary outcomes of patients who
registered during specified previous quarters [2].
During quarterly supervision, teams of at least two
individuals (including a representative from the MoH
national or regional office along with a MoH clinical
officer or nurse) visit each site for up to a full day. Add-
itional representatives from the health sector, including
other MoH staff or non-governmental organization part-
ners, join teams on occasion. Currently, quarterly super-
vision requires ten teams to be in the field for two to
three weeks each at a cost of approximately $60,000 per
quarter (excluding staff salaries). The quarterly supervi-
sion activity is coordinated by the monitoring and evalu-
ation (M&E) team at the Department for HIV and AIDS
in the MoH and funded through the U.S. President's
Emergency Plan for AIDS Relief (PEPFAR) and the Glo-
bal Fund to Fight AIDS, Tuberculosis and Malaria.
These visits provide an opportunity to identify any pro-
blems at the sites, to discuss difficult cases with medical
staff, and to monitor drug stocks, thus improving the
overall quality of care [5].
The supervision teams also review the patient cohort
analyses produced by the ART staff and clean patient
data and aggregate quarterly and cumulative reports on
44 data elements. These data are used for drug forecast-
ing, monitoring overall program performance, identify-
ing gaps in care, and as early warning indicators for HIV
drug resistance [6-18], and therefore maintaining high
quality data is of utmost importance. Like other national
treatment programs, Malawi has strived since its
inception to provide complete, accurate and up-to-date
data. Common errors include incomplete registers, fail-
ure to update follow-up outcomes, duplicate entries, and
incorrect/missing records [5]. In 2008, Makombe et al
reported that unchecked site-produced reports resulted
in a 12% undercount of patients on ART, affecting the
programs ability to precisely forecast future drug needs
[19].
Currently every patient treatment card is reviewed and
compared against the entries in the register during
supervision visits to ensure up-to-date and accurate data
in the register prior to data extraction. Inconsistencies
or incomplete data are updated as appropriate. This
process can take many hours at each visit, competing
with other important aspects of supervision and mentor-
ing. Further, this full audit of patient records by the
supervision team may not yield any changes, especially
at sites where experienced clinic staff have correctly
updated treatment cards and clinic registers in prepar-
ation for the supervision visit.
While the quality of recording for certain key elements
(such as outcome status or regimen) seem to have
improved with repetition of this intensive data cleaning
process, there remain significant challenges in quality of
secondary elements, such as pill counts and side effects.
The goal of this study was to analyze the types and fre-
quency of data errors currently observed in the national
HIV treatment program and to evaluate their impact on
management and monitoring. Based on these findings
we evaluated the performance of a lot quality assurance
sampling (LQAS) algorithm to prioritize ART sites with
poor data quality for a full review of their records before
aggregation of quarterly reports. We then estimated the
potential amount of time saved by omitting an exhaust-
ive review of all treatment cards at sites that pass the
LQAS assessment. Further, we estimated secondary out-
comes from treatment cards during the sampling
process.
Methods
Site Visits
From 11 to 22 January 2010, a study team joined super-
vision teams for the 4
th Quarter (Q4) 2009 supervision.
Twenty-three sites were chosen. Selection was not ran-
dom, but purposely sampled to achieve diverse represen-
tations in terms of geography, size, length of providing
treatment, and public/private sectors. As per MoH
standard, the clinics were informed of the visit by the
supervision team but were not aware that the team
would be accompanied by a study team. Although the
study team visited all 23 clinics; four were excluded be-
cause they either had not initiated any patients on treat-
ment or the patient treatment card filing system had not
yet been created. At each site, the study team recorded
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the supervision team including the type of discrepancy,
the information recorded in the treatment card and
register, and the correct (updated) information. The
study team randomly sampled from the list of all
patients enrolled at the site, found the corresponding
treatment cards, and recorded the time required for
sampling and selected secondary outcomes of patients
still alive and on treatment (side effects and treatment
adherence; the latter was defined by MoH as eight or
fewer pills remaining since last visit). If a selected treat-
ment card was missing, then the next card was included
in the sample. All data were recorded in real time in an
electronic spreadsheet.
LQAS analysis
We evaluated the impact of an LQAS system that classi-
fied each site either as high or as low data quality. The
proposed system randomly sampled treatment cards and
compared the sample of treatment cards to the register.
Based on the results from these samples, sites were clas-
sified and only sites classified as low data quality would
receive an exhaustive review of treatment cards and reg-
isters during supervision.
The sample size required was determined by LQAS
methodology [20,21]. Thresholds for classification as
determined by the M&E team at the Department for
HIV and AIDS at the MoH, were: high data quality if
there was 95% or better concordance between the treat-
ment cards and register (with an allowable 10% risk of
misclassification) and low data quality if concordance
between the treatment card and register was 85% or less
(with an allowable 5% risk of misclassification). Con-
cordance between treatment card and register is defined
as complete agreement on primary outcomes (current
status and treatment regimen, if alive). Based on the bi-
nomial distribution, the minimum sample size required
to meet these constraints was 76 (n=76), with a corre-
sponding decision rule of 7: i.e. a site with less than 7
discrepancies in the 76 sampled treatment cards would
be classified as high data quality and a site with 7 or
more discrepancies classified as low data quality (see
Figure 1a). We also investigated a more conservative
rule for site classification: with “high data quality”
defined as 99% or more concordance between the treat-
ment card and register and “low data quality” defined as
89% or less concordance. Fixing the sample size at 76,
based on the binomial distribution we arrived at a deci-
sion rule of 3 for this sample size (see Figure 1b).
To evaluate the LQAS tool, random sampling of 76
records was done in parallel to the standard supervision
process, where complete review and comparisons of
treatment cards to registers was performed by the ART
supervisors.
Analysis
We compared basic site characteristics (patient burden,
public versus private, length of time providing treatment,
certificates of excellence) using frequencies. We also
used counts to compare updated versus unchanged pa-
tient outcomes and treatment regimens, if alive. Second-
ary data outcomes (pill count and adherence) were
restricted to patients alive and on treatment. These out-
comes are reported with binomial confidence intervals
at the site level, and aggregated using stratified sampling
analysis, weighting by site size. Analyses and graphs were
produced in Stata v.11 and R v.2.0.1.
Ethical approval
All data were collected as part of standard clinical super-
vision and monitoring practices. Data were extracted
from patient cards and registers and there was no direct
contact with patients. This activity was an evaluation
and quality improvement activity for the Department for
HIV and AIDS. The whole process was reviewed and
cleared by the Harvard School of Public Health and the
Harvard Medical School IRBs.
Results
Table 1 summarizes characteristics of the 19 sites
included in the study. Four (21%) had initiated fewer
than 100 patients at the site, six (32%) 101–500 patients,
three (16%) 501–1000 patients, and six (32%) more than
1000 patients, a similar distribution to 249 out of 279
static ART clinics in the national treatment program that
had initiated patients by the end of Q4 2009. The sample
included fewer public clinics, and on average, the
sampled sites had provided treatment longer than those
in the general national treatment program. Only five
(33%) of the sites received a certificate for excellent per-
formance (with “performance” including measures of
data quality and record keeping) at the previous supervi-
sion visit, a lower rate than in the national program.
A total of 16,561 individuals had ever registered for
ART at all sites. The exhaustive comparisons and clean-
ing of the treatment cards to the register took 28.5 hours
total for the 19 sites. Extrapolating to all sites, we esti-
mate 374 team-hours are dedicated to data cleaning at
the 249 sites every quarter. During the exhaustive re-
view, the supervision team identified few discrepancies
in outcomes and treatment regimens when comparing
the treatment card and register (median percent of
records with discrepancies, 1.0%; IQR: 0.5%-3.0%). Of
the 210 discrepancies between records (1.2%) in out-
comes, a majority (58%) were incorrect in both the treat-
ment card and the register, often as a result of a patient
who had defaulted treatment and neither record had
been updated. For 34% of the outcome errors, the
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updated), and in the remaining 8% the register was
correct.
For the 11,034 patients alive and on treatment at the
sampled sites, only 50 (0.4%) had discrepancies in treat-
ment regimens recorded in their treatment card and
register. Most often (94%), regimen changes had been
recorded in the treatment card, but not updated in the
register; the remaining were correct in the register (4%)
or neither the treatment card nor the register (2%). For
the 2,605 patients who initiated treatment in Q4 2009,
378 (15%) had discrepancies in their registration data
(gender, age group, transfer status, TB history). The
treatment card was determined correct in 71% of these
errors, the register in 21% and neither in 8%. Usually this
resulted from incorrect WHO clinical staging deter-
mined from the documented clinical conditions (where a
person with a Stage IV condition would be listed as
Stage III or vice versa), or TB status was incorrectly
recorded as current instead of TB in the previous two
years.
Since summary measures on outcomes and treatment
regimens are extracted from the register, we explored
the impact of relying on the registers in their original
state versus the registers after a full review and update.
Using the register without updates led to a 1.2% over-
count in the number alive and on treatment, and a 5.6%
undercount in the number of defaulters (Table 2). The
uncorrected register data also overcounted by 0.4% the
number on first-line treatment, and undercounted those
on a zidovudine substitute and efavirenz substitute regi-
mens by 3.6% and 9.7%, respectively. None of the site
factors identified previously [19] were significant predic-
tors of low data quality, possibly due to low power since
so few sites were visited (results not shown).
At 16 sites, we randomly sampled 76 patient treatment
cards. The remaining three had fewer than 76 cards
inspected because fewer than 76 patients had ever
initiated treatment at that site. At these three sites, the
classification was made on the exhaustive review. LQAS
classification of sites with the 85%/95% thresholds would
have reduced the time needed for record review from
Figure 1 Operating Characteristic Curves for the two LQAS classifications. The curves plot the probability of site being classified as ‘high
data quality’ based on the LQAS procedure for a given level of concordance between treatment cards and the register. Figure 1a is the plot for
the 85%/95% classification. Figure 1b is the plot for the 89%/99% classification, superimposed on top of the 85%/95% classification. Each point
represents a clinic, plotted at their true level of concordance between the treatment cards and register based on exhaustive review at the site.
Circles indicate sites that are classified as ‘low data quality’ based on the LQAS classification. Triangles indicate sites that are classified as ‘high
data quality’.
Table 1 Site Characteristics
Characteristics of sites Sites included National ART program
n=19 n=249
Patient burden
100 patients or fewer 4 21% 52 21%
101 - 500 patients 6 32% 72 29%
501 - 1000 patients 3 16% 39 16%
more than 1000 patients 6 32% 86 35%
Public clinics 13 68% 199 80%
Length of time providing treatment
†
3 months or less 3 16% 13 5%
3 months to 2 years 3 16% 73 29%
2 to 4 years 3 16% 103 41%
more than 4 years 10 53% 60 24%
Certificate given at last
supervision visit
(n=15) (n=204)
5 33% 98 48%
† Restricted to public sector sites. Originally, private and public sector sites
were supervised separately. As a result, the national ART program records do
not document length of time providing treatment for all private sector sites
and these were excluded.
Hedt-Gauthier et al. BMC Health Services Research 2012, 12:196 Page 4 of 8
http://www.biomedcentral.com/1472-6963/12/19628.5 to 8 hours (see Table 2). Based on the exhaustive re-
view, 16 sites had “high data quality” (95% or more
agreement between treatment cards and register entries)
and all of these sites would have been correctly classified
using the LQAS system (Table 2 and Figure 1). “One site
had less than 85% concordance between records, and
this site would have been classified as low data quality
via LQAS. For the two sites with concordance between
85-95%, one site would have been classified as low data
quality. Because only two sites were classified as “low
data quality” and thus would have received exhaustive
review, there were very few updates to the aggregated
data extracted from the register. The only marked im-
provement was a reduced undercount of numbers on
the substituted zidovudine regimen (from 3.6% to 2.8%).
We also investigated the more conservative rules for
site classification, with “high data quality” defined as
99% or more concordance between the treatment card
and register and “low data quality” defined as 89% or less
concordance. The nine sites with greater than 99% con-
cordance based on the exhaustive inspection were cor-
rectly classified as “high data quality” by LQAS. The one
site with “low data quality” was also correctly classified.
The subsequent exhaustive review at the one additional
site identified with this more conservative classification
rule improved the accuracy of the aggregate measures
extracted from the register, halving the percent errors on
nearly all measures and reducing the undercount of efa-
virenz substitutes to only one third of its previous size
(from 9.7% undercount to only 3.1% undercount). This
increased accuracy required half of the time currently
required for chart review at sites, though it increased the
time by 50% over the less conservative (85%/95%) LQAS
approach.
Table 3 reports the site specific estimates of side
effects and adherence in patients alive and on treatment
for the 16 sites where sampling was employed (sites with
fewer than 76 patients were excluded). At these 16 sites,
41% to 97% of the sampled treatment cards were from
patients who were alive and on treatment. Of those alive,
between 62-100% had presence or absence of a side ef-
fect recorded. For those with recorded side effects, per-
cent with side effects range from 0-27%, with a median
of 3.3%. Based on the sample, the estimated proportion
of patients alive with side effects was 7.2% (95% CI: 4.8-
9.6%). For adherence, pill counts are only conducted on
individuals alive and on 1
st line treatment, 39-92% of the
original sample. For each site, 60-100% of eligible indivi-
duals had pill counts recorded and amongst these indivi-
duals, patient adherence ranges from 68-100%, with a
median of 85.3%. The estimated proportion of patients
alive that were adherent was 86.3% (95% CI: 82.8-89.8%).
Discussion
Because of the extensive use of the national ART
program data for management and analysis of patient
care, ensuring the quality of this data is critical. Poor
data can lead to imprecise budgeting and procurement
of drugs, incorrect inference on program performance,
and inappropriate adaptations to program implementa-
tion and, ultimately, poor patient care. Like other coun-
tries, Malawi has strived to improve and maintain data
quality. As evident in these results, the overall level of
quality is currently high for critical elements, but the
system in place to produce this quality is expensive, time
consuming, and can be redundant as many sites have
already reviewed and cleaned data prior to supervision
visits. Excluding travel time, nearly 750 team-hours
every three months are spent at sites, and this time bur-
den will only increase as more patients initiate treat-
ment. We attribute half of this time solely to the data
cleaning process and reducing the time for data cleaning
can translate into budget savings for the ART program
or, perhaps more importantly, into reallocation of time
during supervision visits to more crucial activities such
as mentoring or discussing difficult cases. With the LQAS
system, we save time while maintaining the current
Table 2 Impact of LQAS classification systems
System
without
any
review
of data
quality
LQAS Triaging LQAS Triaging
Upper
threshold=95%
Upper
threshold=99%
Lower
threshold=85%
Lower
threshold=89%
n (sample size) N/A 76 76
d (decision rule) N/A 7 3
Number of sites above
the upper threshold
N/A 16 9
Number classified as
high data quality
N/A 16 9
Number of sites below
the lower threshold
N/A 1 1
Number classified as low
data quality
N/A 1 1
Differences between updated
and non-updated data
Alive +1.2% +1.2% +0.7%
Default −5.6% −5.8% −2.8%
1st Line Rx +0.4% +0.3% +0.1%
Substitute, AZT −3.6% −2.8% −1.5%
Substitute, EFV −9.7% −9.7% −3.1%
Time Required
for Review
N/A 8 hours;5 minutes 13 hours;19 minutes
Design and error rates in reporting under systems with a) no review process,
b) LQAS classification system with pu=0.95 and pl=0.85, and c) LQAS
classification system with pu=0.99 and pl=0.89. AZT=zidovudine.
EFV=efavirenz.
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challenges and associated consequences of poor data qual-
ity in health programs and each provides a method for
measuring data quality, including some that rely on LQAS
[19,22-34]. However, one unique benefit of this LQAS-
based system is that the assessment is integrated into rou-
tine supervision. The simplicity of the procedure allows
the classification to happen on site and immediately links
to actions that improve data quality, such as the exhaust-
ive data review in this case.
Based on these results, we recommend the following
data cleaning strategy for the ART program in Malawi.
1. Complete an exhaustive data cleaning process at
sites with fewer than 500 patients ever initiated.
These sites should have an exhaustive review
because error rates are often higher at smaller, less
experienced sites such as these, because they have
less practice with forms and are unlikely to have a
designated data clerk. Further, the review at small
sites is less time consuming, reducing the benefit of
a sampling process.
2. Exhaustive review of all patients initiating in the last
quarter at every site. Basic patient characteristics are
collected once at registration and had high error
rates (15%). Correcting these errors at the first
supervision visit after initiation prevents them from
recurring across future reports.
3. For the public sites with more than 500 patients,
sample 76 treatment cards from patients who
initiated treatment before the last quarter and
compare these against the register. Only complete an
exhaustive review if 7 or more inconsistencies are
identified. The LQAS system with 85%/95%
thresholds maintains data quality sufficient for
program purposes and minimizes time required for
data review/cleaning. We also recommend collecting
information on secondary outcomes such as pill
count and side effects during the sampling process.
Because time required for the exhaustive review was not
separated by new and formerly registered patients, we
could not estimate the exact time savings of this system.
However, we expect the overall savings to remain signifi-
cant since less than 16% of records were from new initi-
ates. Further, the estimated time savings attributable to
LQAS reviews at the small sites was small relative to the
overall time savings (3 of the 20.5 hour reduction). The ex-
trapolation regarding number of team hours taken to
clean data each quarter assumed the same average quality
of data across all clinics in Malawi, which given the pur-
posive nature of our sampling may not be the case. An-
other limitation of this study, and perhaps the LQAS
system for supervision, is the skipping of the patient treat-
ment cards if the card was not available during the sam-
pling procedure. Out of the records sampled, an average
Table 3 Secondary analysis of side effects and pill counts
Side effects Adherence
Number alive
in sample
Number with side
effects recorded
Percent with
adverse side
effects
95% Confidence
interval
Number alive
and on 1st line
in sample
Number with
PC recorded
Percent with
good adherence
95% Confidence
interval
Site 1 49 47 2.1% 0.1% 11.3% 49 46 69.6% 54.2% 82.3%
Site 2 42 26 7.7% 0.9% 25.1% 39 29 89.7% 72.6% 97.8%
Site 3 47 41 14.6% 5.6% 29.2% 43 39 94.9% 82.7% 99.4%
Site 4 59 55 1.8% 0.0% 9.7% 57 47 87.2% 74.3% 95.2%
Site 5 58 55 0.0% 0.0% 6.5% 56 53 77.4% 63.8% 87.7%
Site 6 45 36 5.6% 0.7% 18.7% 39 31 80.6% 62.5% 92.5%
Site 7 44 44 0.0% 0.0% 8.0% 44 43 100.0% 91.8% 100.0%
Site 8 32 28 7.1% 0.9% 23.5% 30 28 85.7% 67.3% 96.0%
Site 9 44 33 15.2% 5.1% 31.9% 32 13 92.3% 64.0% 99.8%
Site 10 39 38 2.6% 0.1% 13.8% 39 39 74.4% 57.9% 87.0%
Site 11 31 27 3.7% 0.1% 19.0% 30 26 92.3% 74.9% 99.1%
Site 12 73 69 2.9% 0.4% 10.1% 70 65 67.7% 54.9% 78.8%
Site 13 41 34 2.9% 0.1% 15.3% 38 33 84.8% 68.1% 94.9%
Site 14 74 59 0.0% 0.0% 6.1% 65 56 85.7% 73.8% 93.6%
Site 15 57 49 26.5% 14.9% 41.1% 39 32 78.1% 60.0% 90.7%
Site 16 48 45 6.7% 1.4% 18.3% 41 34 76.5% 58.8% 89.3%
Total 7.2% 4.8% 9.6% 86.3% 82.8% 89.8%
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time of the visit. While some of these records were simply
lost, often the records were not available because the pa-
tient was in the clinic receiving care during the supervi-
sion visit. Since most discrepancies were for patients who
are no longer alive and on treatment, or who have
defaulted, excluding these records likely increases the
chance of classifying sites as having poor data quality and
following up with a exhaustive data review. An additional
limitation of this study (and the proposed supervision sys-
tem) is the missing data on secondary outcomes from pa-
tient records. This likely biases the estimates of secondary
outcomes, especially side effects where no record of side
effects often suggests none are detected. We believe that
active recording of secondary outcomes through the pro-
posed supervision system could actually lead to improved
documentation, as clerks and health workers will receive
feedback during the process if the data is not recorded. Fi-
nally, while we believe the effect to be minimal since sites
were not informed of the study team ahead of time, there
could be some Hawthorne effect on the rigor of the super-
vision process. The Hawthorn effect could also affect the
speed and accuracy of the ART supervision team, which
would impact our estimates of time required for data
cleaning as well as time saved using the LQAS system.
Additional concerns are raised when proposing a sam-
pling approach for monitoring data quality. One is that
failure to identify low data quality sites translates into in-
accurate aggregated reports. The proposed algorithm
has been designed to minimize this risk – sites with 85%
or lower concordance between the treatment card and
register have less than a 5% risk of being classified as
high data quality at a single visit. As the data quality gets
worse the chance of misclassification becomes even
smaller, decreasing to less than 1% if the concordance
goes down to 80%. This thus results in a very small po-
tential for bias in the aggregated measures. Another con-
cern is that sites may accumulate errors over time or
that the site clerks may become less diligent if the ex-
haustive review is not completed. However, because the
LQAS process is repeated independently each quarter,
sites with degrading quality, if not captured at one visit,
will likely be captured at future visits. Further, during
previous rounds of supervision, clerks and health work-
ers have expressed dissatisfaction at the automatic ex-
haustive review noting the duplication of their efforts
and the impression that the supervision teams do not
trust their work. The LQAS system addresses these con-
cerns by prioritizing and conducting exhaustive reviews
only at sites with poor data.
Conclusion
In this paper, we describe the development of a simple
LQAS system to assess data quality of sites. The LQAS
classification is conducted independently at each visit;
however the method could be extended so that perform-
ance at previous data quality assessments can be incorpo-
rated into the decision to conduct exhaustive review at a
subsequent visit. Further, the Department for HIV and
AIDS may still opt for exhaustive review at sites under
special circumstances, such as immediately following
guideline changes or changes in personnel at a site. Before
any LQAS-based system can be implemented, forms to
support the LQAS process must be developed and super-
vision teams need to be trained. The LQAS system, al-
though straightforward to implement, is more complicated
than the current methods that are standardized across all
sites. However, supervisors would most likely welcome the
system due to the substantial time saved. The LQAS system
is unlikely to be a long-term solution for rapidly expanding
ART programs such as in Malawi, it would provide a mid-
term solution to ensure adequate quality of data until a reli-
able and sustainable system, such as an electronic record
system, could be introduced nationwide [35]. Further, the
system illustrated here can be readily adapted by other na-
tional programs using paper-based systems to ensure high
quality data.
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